Palvella Therapeutics Chief Operating Officer Kathleen Goin sold 4,302 shares for approximately $476,000 at a weighted average price of $110.73 per share, according to an SEC filing. The transaction was executed under a Rule 10b5-1 trading plan adopted in August 2025 and reduced her direct common stock holdings to zero, though she retains 17,219 outstanding stock options. The sale comes after Palvella shares surged nearly 620% over the past year, closing at $148.21 on June 26, 2026, amid optimism for its lead therapy QTORIN rapamycin. The FDA recently granted rolling review for the company's New Drug Application in microcystic lymphatic malformations, with management targeting completion of the submission in the second half of 2026.
Palvella Therapeutics, IncFDA granted rolling review for NDA in microcystic lymphatic malformations, a key regulatory milestone.